Sports doping statistics vary sharply according to whether they measure self-reported use, indirect estimates, laboratory findings, tests, or adjudicated cases. The figures below make those definitions, populations, periods and geographic scopes explicit.
Key Sports Doping Statistics
The following figures summarize the most useful measures across research and official anti-doping programs:
- In a 2015 review of adult elite-athlete subgroups, intentional doping was estimated at 14–39% across specific groups.
- In the same 2015 review, annual doping-control-test estimates were 1–2% among elite-sport testing populations.
- Across questionnaire studies reviewed in 2015, reported doping estimates ranged from 1% to 70% depending on sport, level and definition.
- A systematic review of competitive-sport research published from 1975 through 2019 found reported prevalence ranging from 0% to 73%.
- That 1975–2019 evidence synthesis represented 102,515 competitive-sport participants, including 72.8% men and 27.2% women.
- An indirect-estimation meta-analysis found 22.6% lifetime prevalence among multi-sport competitive athletes in its included studies.
- The same meta-analysis found 12.7% lifetime prevalence among single-sport competitive athletes.
- In the meta-analysis, 14.1% past-year prevalence was estimated for multi-sport competitive-athlete samples.
- In 2023, WADA recorded 1,199 anabolic-agent adverse analytical finding occurrences across all sports in ADAMS.
- WADA recorded 533 diuretic and masking-agent adverse analytical finding occurrences across all sports in 2023.
- In 2023, EPO appeared in 93 peptide-hormone-class adverse analytical finding occurrences, representing 55% of that class.
- USADA completed 9,645 anti-doping tests in 2023 across its programs.
- USADA initiated 96 potential doping-violation cases in 2023.
- USADA declared 322 whereabouts failures in 2023 from 426 potential-failure notices.
- USADA’s 2023 High Risk List contained 391 stimulant-category products.
- A U.S. elite-athlete survey with 1,398 respondents estimated 6.5–9.2% past-12-month use of at least one prohibited substance or method without a TUE.
- In that U.S. survey, in-competition cannabinoid use was 4.2% during the 12 months before the survey.
- U.S. elite-athletes estimated that 11.2% of athletes in their sport were doping on average, a perception measure rather than measured use.
Contents
- Prevalence estimates and what they measure
- WADA testing and adverse analytical findings
- Prohibited substances in the 2023 data
- USADA tests, cases and whereabouts
- Supplements, surveys and detection limits
Sports Doping Statistics: Prevalence Estimates and What They Measure
There is no single prevalence number for sports doping. A 2015 review estimated intentional doping among current adult elite athletes at 14–39% in specific subgroups, while annual doping-control-test estimates were 1–2%; the review emphasized that detection-based estimates are not equivalent to true use prevalence. Prevalence of doping use in elite sports: a review of numbers and methods
Questionnaire-based estimates in that review ranged from 1% to 70%, reflecting different sports, competitive levels and definitions. The broad spread is therefore a measurement issue as well as a possible difference in behavior.
A later evidence synthesis covered 105 studies published from 1975 through 2019. Reported prevalence across those competitive-sport studies ranged from 0% to 73%, although most results were below 5%; the authors caution that the range combines different methods, sports and definitions. Doping Prevalence in Competitive Sport: Evidence Synthesis with Best Practice Recommendations
The composition of that evidence base also matters:
- 89 studies used self-reported survey data, while 17 used sample-analysis data and one used both.
- The studies represented 102,515 athletes, of whom 72.8% were men and 27.2% were women.
An indirect-estimation meta-analysis searched records through March 2025. It included 46 records, with 30 records and 34 independent studies in the quantitative synthesis; these counts describe the evidence corpus rather than a population prevalence estimate. Doping Prevalence in Sport from Indirect Estimation Models: A Systematic Review and Meta-analysis
| Population in included studies | Lifetime prevalence | Past-year prevalence |
|---|---|---|
| Multi-sport competitive athletes | 22.6% | 14.1% |
| Single-sport competitive athletes | 12.7% | 12.7% |
| Multi-sport recreational sportspersons | 15.0% | 8.7% |
| Single-sport recreational sportspersons | 15.4% | 15.5% |
These are pooled indirect-estimation-model results from studies with varying periods and samples, not a census of all athletes or sport participants.
Sports Doping Testing Statistics from WADA Laboratories
WADA’s 2023 Anti-Doping Testing Figures report adverse analytical finding, or AAF, occurrences by substance class across all sports in ADAMS. An AAF is not the same as an adjudicated or sanctioned anti-doping rule violation; multiple findings can be linked to one athlete or sample, and some findings may undergo therapeutic-use-exemption review. 2023 Anti-Doping Testing Figures
The 2023 class-level counts were:
| Substance class | AAF occurrences | Measurement scope |
|---|---|---|
| Anabolic agents | 1,199 | All sports in ADAMS, 2023 |
| Other anabolic agents | 173 | All sports in ADAMS, 2023 |
| Peptide hormones and related substances | 169 | All sports in ADAMS, 2023 |
| Beta-2 agonists | 62 | All sports in ADAMS, 2023 |
| Hormone and metabolic modulators | 323 | All sports in ADAMS, 2023 |
| Diuretics and masking agents | 533 | All sports in ADAMS, 2023 |
| Stimulants | 464 | All sports in ADAMS, 2023 |
| Narcotics | 40 | All sports in ADAMS, 2023 |
These counts should be read as laboratory finding occurrences, not unique people using a substance. They also should not be combined with WADA’s 2022 anti-doping rule violation report as though the two publications formed one trend series, because they use different concepts and periods.
Which Prohibited Substances Appear Most Often in Sports Doping Statistics?
Within the 2023 WADA AAF data, several individual substances accounted for notable portions of their respective classes:
- EPO accounted for 93 occurrences, or 55% of peptide-hormone-class occurrences, while darbepoetin accounted for 24 occurrences, or 14%.
- Ostarine accounted for 69 occurrences, or 40% of other anabolic-agent findings; clenbuterol and LGD-4033 each accounted for 34 occurrences, or 20%.
- Meldonium accounted for 77 occurrences, or 24% of hormone and metabolic-modulator findings, while clomifene accounted for 59, or 18%.
- Furosemide accounted for 161 occurrences, or 30% of diuretic and masking-agent findings; hydrochlorothiazide accounted for 82, or 15%.
- Methylphenidate accounted for 115 stimulant occurrences, or 25%, while cocaine accounted for 73, or 16%.
- Carboxy-THC accounted for all 136 cannabinoid AAF occurrences in 2023.
- Prednisolone accounted for 50 occurrences, or 34% of glucocorticoid findings.
The percentages above are within-class shares reported for AAF occurrences. They do not represent the share of athletes, the probability of use, or the share of final sanctions.
USADA Testing, Violation and Whereabouts Statistics
USADA completed 9,645 tests in 2023: 2,657 in-competition and 6,988 out-of-competition. Tests are samples or test events, not unique athletes or sanctions. Testing Numbers | U.S. Anti-Doping Agency
| USADA measure | 2023 figure | Scope |
|---|---|---|
| In-competition tests | 2,657 | USADA programs |
| Out-of-competition tests | 6,988 | USADA programs |
| Total tests | 9,645 | USADA programs |
| Potential doping-violation cases initiated | 96 | USADA |
| Cases resulting in sanctions | 18 | USADA |
| Cases resulting in no violation | 51 | USADA |
| Cases pending at year-end | 26 | USADA |
USADA’s quarterly totals were 1,971 tests in 2023 Q1, 2,919 in Q2, 2,918 in Q3 and 1,837 in Q4. The case outcomes can be resolved after the reporting period, so initiated cases should not be treated as final sanctions.
USADA also issued 426 potential whereabouts-failure notices in 2023 and declared 322 to be failures. These failures are an anti-doping rule category, not proof that an athlete used a prohibited substance. USADA 2023 Annual Report
What Sports Doping Statistics Say About Supplements and Detection Limits
USADA’s 2023 High Risk List contained 141 products in the S1 anabolic-agent category, 117 in the S2 peptide-hormone category and 391 in the stimulant category. A risk-list count is not a prevalence-of-use estimate or a contamination rate, and products may contain ingredients from multiple categories. USADA 2023 Annual Report
Supplement Connect served more than 7,000 users in 2023. Service use measures engagement with a public resource, not doping behavior.
A peer-reviewed study of U.S. Olympic, Paralympic, world and national-level athletes subject to a Code-compliant testing program included 1,398 respondents. Depending on how inconsistent responses were handled, 6.5–9.2% reported past-12-month use of at least one prohibited substance or method without a therapeutic-use exemption. Doping Prevalence among U.S. Elite Athletes Subject to Drug Testing under the World Anti-Doping Code
The survey’s category-specific results included:
- In-competition cannabinoid use was 4.2% during the 12 months before the survey.
- Diuretics or masking agents and stem-cell or gene-editing categories each measured 0.1%.
- Narcotics and hormone or metabolic modulators each measured 0.2%.
The study’s 9.2% method classified 128 respondents as doping, while the stricter method produced 6.5%; these are alternative scoring rules, not independent populations. Respondents estimated that an average 11.2% of U.S. athletes in their sport were doping, but that is perceived prevalence and the authors caution that normative estimates can overestimate behavior.